HC Wainwright Comments on Zevra Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – HC Wainwright dropped their Q3 2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Monday, September 30th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings of ($0.50) per share for the quarter, down from their previous forecast of ($0.48). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.74) EPS and FY2025 earnings at ($0.30) EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. The company had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. During the same period last year, the business earned ($0.15) earnings per share.

A number of other analysts have also issued reports on ZVRA. JMP Securities started coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price objective on the stock. Roth Mkm boosted their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Canaccord Genuity Group dropped their target price on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, September 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a report on Tuesday. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Zevra Therapeutics presently has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA opened at $6.85 on Wednesday. The company has a market cap of $286.69 million, a P/E ratio of -5.07 and a beta of 1.94. Zevra Therapeutics has a one year low of $3.89 and a one year high of $8.95. The business’s 50-day simple moving average is $7.17 and its 200 day simple moving average is $5.76. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00.

Insiders Place Their Bets

In related news, Director Thomas Anderson bought 10,000 shares of the business’s stock in a transaction dated Tuesday, July 16th. The shares were acquired at an average price of $6.81 per share, for a total transaction of $68,100.00. Following the purchase, the director now owns 20,000 shares in the company, valued at approximately $136,200. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders purchased a total of 22,000 shares of company stock valued at $140,340 in the last ninety days. Corporate insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD acquired a new position in Zevra Therapeutics in the first quarter worth $64,000. The Manufacturers Life Insurance Company grew its position in shares of Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares during the last quarter. Focus Financial Network Inc. ADV acquired a new stake in Zevra Therapeutics during the fourth quarter worth about $141,000. Virtu Financial LLC bought a new position in Zevra Therapeutics in the fourth quarter worth about $177,000. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after acquiring an additional 17,557 shares during the period. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.